Significance Statement {#s1}
======================

Recently, interest in clozapine N-oxide (CNO) has increased due to its exploitation as a ligand for the engineered G-protein-coupled receptors (GPCRs) in the chemogenetic 'Designer Receptors Exclusively Activated by Designer Drugs' (DREADD) system. Our results highlight that in the experimental design there is a necessity for the inclusion of a group of animals which do not express DREADDs, but are given the same dose of CNO as the DREADD expressing animals. Currently, only a small minority of studies using DREADDs employ this control. There needs to be careful consideration of the CNO dose being administered and of the possible biological effects of CNO.

Introduction {#s2}
============

Clozapine N-oxide (CNO) is a major metabolite of the anti-psychotic drug clozapine. While clozapine is known to bind to many receptors ([@B14]; [@B49]; [@B41]), the few studies that investigated the pharmacological actions of CNO failed to find any effects. This has led to the consensus that CNO is largely an inactive metabolite ([@B3]; [@B48]; [@B60]). However, administration of CNO leads to detectable levels of clozapine in the plasma of humans and guinea pigs ([@B30]; [@B11]). The retroconversion of CNO to clozapine in rats is somewhat controversial as [@B30] were unable to detect clozapine in the plasma of Wister rats after administration of CNO (1 mg/kg, i.p.), but [@B34] were able to detect clozapine, *N*-desmethylclozapine (*N*-Des) and other minor clozapine metabolites in the urine of Lewis rats (20 mg/kg, oral; [@B34]). It is unclear whether the difference is due to differing strain, sample preparation, dosage, detection sensitivity, or due to one group assessing plasma and the other urine. It has been noted that species differences in the endogenous production of ascorbate, which perturbs CNO retroconversion *in vitro* ([@B43]) could help to explain the differences in CNO retroconversion. Nevertheless, there is evidence for reversible metabolism whereby clozapine is metabolized into *N*-Des and CNO, with a portion of the CNO being reduced back to the parent compound which presumably is then metabolized back into CNO in an ever diminishing cycle leading to eventual clearance ([@B43]). Therefore, all experiments that utilize CNO should verify that in the species and strain being employed, the administration of CNO does not have effects.

Recently, interest in CNO has increased due to its exploitation as a ligand for the engineered G protein-coupled receptors (GPCRs) in the chemogenetic Designer Receptors Exclusively Activated by Designer Drug (DREADD) system. Briefly, this system consists of a family of synthetic GPCRs (based upon the muscarinic M3 and M4 subtypes), which are not believed to be activated by any endogenous ligand but which are potently activated by the otherwise inert molecule CNO ([@B5]). This is an extension of a previous Receptor Activated Solely by a Synthetic Ligand (RASSL) concept ([@B15]; [@B46]), with the key functional advantage being that, unlike the RASSL system, where the activating ligand has affinity for endogenous receptors within the CNS, in the DREADD system the ligand (CNO) is believed to be inert, that is, to have no biological activity. The ability to express DREADD receptors in neurons *in vivo* completes a system whereby the receptor, coupled to a downstream signaling cascade of choice \[inhibition (Gi); depolarization and burst firing; increases in cAMP\] is expressed in a neuronal subtype of interest (e.g., via stereotaxic infusion of virus particles), which can then be selectively and exclusively manipulated by the systemic administration of CNO ([@B21]; [@B63]). This is a potentially powerful research and therapeutic toolbox, which has already yielded novel insights into brain--behavior relationships. We chose to use this system to ask the following simple yet important question: can the behavioral effects we have previously seen following permanent lesions of a specific neuronal population also be induced by transient (DREADD-Gi) inhibition of the same neuronal population? Our initial results were somewhat surprising as we repeatedly observed that CNO-treated, non-DREADD, wild-type control rats were impaired in the behavior we predicted to be affected by DREADD-Gi inhibition. That is, in the absence of any DREADD receptor, we were observing behavioral effects of CNO. This was a major hurdle in interpreting our results. Therefore, before pursuing our DREADD experiments in alternative behaviors of interest, we undertook a series of control experiments, which are reported here. Using wild-type male Long--Evans rats, we investigated the effects of CNO at commonly used doses (1--5 mg/kg) on acoustic startle response (ASR), prepulse inhibition (PPI) of ASR, NMDA- and muscarinic-induced disruption of PPI, spontaneous locomotion, and amphetamine (AMPH)-induced hyperlocomotion. In addition, by use of fast-scan cyclic voltammetry (voltammetry), we assessed the effects of CNO on evoked dopamine (DA) release in the nucleus accumbens (NAcc). Finally, we analyzed plasma from CNO-treated rats by HPLC for detection of CNO, clozapine, and *N*-Des.

Materials and Methods {#s3}
=====================

Male Long--Evans rats (Harlan Laboratories; rats were bred in our facilities) weighing 300--330 g at the start of behavioral studies and 300--450 g for voltammetric studies were maintained single housed in plastic cages in a temperature- and humidity-controlled room. Lights were on a 12 h light/dark cycle (lights on at 7:00 A.M.) with testing conducted during the light phase. Rats had free access to food (Harlan Diet 2018, Harlan Laboratories) and water in the home cage. All experiments were approved by the Institutional Animal Care and Use Committee and conducted in accordance with the National Institutes of Health *Guide for the Care and Use of Laboratory Animals*.

Compounds {#s3A}
---------

CNO was supplied by the National Institutes of Health Drug Supply Program, and was dissolved in DMSO then diluted to a final concentration of 1, 2, or 5 mg/ml CNO in 0.5% DMSO in saline solution. Control injections were 0.5% DMSO in saline solution. Of the 22 articles that we found that used systemic administration of CNO in rats ([@B23]; [@B4]; [@B37]; [@B7]; [@B8]; [@B18]; [@B31]; [@B47]; [@B10]; [@B25]; [@B38]; [@B42]; [@B50]; [@B61]; [@B26]; [@B35]; [@B36]; [@B44]; [@B51]; [@B57]; [@B58]), 2 used chronic treatment (e.g., in drinking water) and 11 used doses \>1 mg/kg. Of those that used doses of \>1 mg/kg, most used doses of 3 mg/kg, but in a few cases doses were as high as 10 mg/kg. Of all the studies using rats and CNO-activated DREADDs that we surveyed, only a few used a non-DREADD CNO control, and most of these used this control in only a subset of the presented experiments. Our selection of 1, 2, and 5 mg/kg doses was based on our preliminary experience with CNO and the few published rat studies that were available at the time. Also, Dr. Roth's research group had shown that in mice there were no effects at doses of 5 mg/kg ([@B2]) and that some mouse studies had used doses as high as 10 mg/kg ([@B45]).

Phencyclidine (PCP; Sigma-Aldrich), [d]{.smallcaps}-amphetamine (Sigma-Aldrich), and scopolamine (Tocris Bioscience) were dissolved in 0.9% saline solution, and injected at 1 ml/kg.

Behavioral testing {#s3B}
------------------

### ASR and PPI testing {#s3B1}

Testing was conducted in startle chambers (Kinder-Scientific). Each sound-attenuating test chamber was equipped with small chambers mounted on a parallelogram load cell (calibrated to newtons) situated directly beneath a loudspeaker. Constant dim illumination was provided by a light within the chamber. Throughout testing, constant background noise was presented as 65 dB of white noise. All startle and prepulses (PPs) were presented as squarewave (instantaneous rise and fall) bursts of white noise. A trial is defined as a startle stimuli (120 dB, 40 ms) preceded by either a PP (various conditions, described in a relevant subsection of Materials and Methods) or no prepulse (for assessment of startle only). The intertrial interval (ITI) is the time (in seconds) between trials, regardless of whether these trials contain a PP or not. The percentage PPI was calculated as \[100 − (mean ASR amplitude on prepulse pulse trials)/mean 120 dB ASR amplitude on pulse alone trials) × 100\]. All rats had an ASR \>1 N on the 120 dB startle-only trials, and all rats were included in the analysis of PPI.

Following 5 min of acclimatization and the presentation of three 120 dB 40 ms pulses with a mean 15 s ITI, rats were exposed to eight trial types, presented 10 times each in a pseudorandom order with a mean ITI of 15 s (range, 5--25 s). Trial types were as follows: startle stimulus only (120, 110, 100, and 90 dB; 40 ms white noise) and four different prepulse plus pulse trials (68, 72, 76, and 80 dB prepulse, 20 ms duration, the onset of which was followed 120 ms later by a 120 db 40 ms pulse).

### CNO-alone studies {#s3B2}

To assess the effects of CNO on startle and PPI, rats were injected with CNO (1 mg/kg, i.p.) or 0.5% DMSO in saline solution 20 min before being placed in the PPI chambers. This dose was chosen based on the literature ([@B4]; [@B37]) and consultation with investigators who had experience using DREADDs.

### Phencyclidine studies {#s3B3}

Knowing the possibility of CNO retroconversion, it was decided to test higher doses of CNO in a bioassay known to be sensitive to the presence of several antipsychotic agents, the disruption of prepulse inhibition by the NMDA antagonist PCP ([@B32]; [@B53]). To assess the effects of CNO on PCP-induced disruption of PPI, rats were assigned to one of the following six experimental groups, each group containing two treatments: (1) vehicle (Veh) and vehicle; (2) vehicle and PCP; (3) CNO 2 mg/kg and vehicle; (4) CNO 5 mg/kg and vehicle; (5) CNO 2 mg/kg and PCP; and (6) CNO 5 mg/kg and PCP. Rats were injected with the first treatment (0.5% saline, i.p., in DMSO or CNO) followed 20 min later by the second treatment (saline or PCP 2.5 mg/kg, both s.c.). They were placed in the PPI chambers 10 min after the PCP injection. Due to there being no significant reversal of PCP-mediated disruption at CNO doses of 2 or 5 mg/kg, lower doses were not pursued.

### Scopolamine studies {#s3B4}

To assess the effects of CNO on scopolamine-induced disruption of PPI, rats were assigned to one of the following four groups, each containing two treatments: (1) vehicle and vehicle; (2) vehicle and scopolamine; (3) CNO 5 mg/kg and vehicle; and (4) CNO 5 mg/kg and scopolamine. Rats were injected with the first treatment (0.5% DMSO in saline or 5 mg/kg CNO, both i.p.) followed 20 min later by the second treatment (saline or 0.5 mg/kg scopolamine, both s.c.). They were placed in the PPI chambers 10 min after the scopolamine injection. In light of the results with PCP, initial studies used 5 mg/kg CNO, and, because no significant reversal was observed, further doses were not evaluated.

### Locomotor testing {#s3B5}

Locomotor testing was conducted in plastic cages measuring 45 × 23 × 20 cm interfaced by a grid array of infrared beams connected to a computer system that tracked and quantified the location and movements of the animal (OMNITECH Instruments). Rats were habituated to the testing room in their home cages for \>30 min prior to testing. To guard against the possibility of a U-shaped dose--response curve, the effects of all three doses of CNO tested above were assessed for effects on spontaneous locomotion and amphetamine-induced hyperlocomotion. Rats were assigned to one of six groups, each containing two treatments. The groups were as follows: (1) vehicle and vehicle; (2) vehicle and amphetamine; (3) CNO 1 mg/kg and vehicle; (4) CNO 2 mg/kg and vehicle; (5) CNO 5 mg/kg and vehicle; (6) CNO 1 mg/kg and amphetamine; (7) CNO 2 mg/kg and amphetamine; and (8) CNO 5 mg/kg and amphetamine. Rats were injected with the first treatment (0.5% DMSO in saline or CNO, both i.p.) and immediately placed in the locomotor cages; 20 min later, they were removed from the cages and injected with the second treatment (saline or 1.5 mg/kg [d]{.smallcaps}-amphetamine, both s.c.), and placed back in the locomotor cages for a further 120 min.

Fast-Scan Cyclic Voltammetry {#s3C}
----------------------------

Rats were anesthetized with urethane (1.5--2.0 g/kg), placed into a stereotaxic apparatus, and implanted with a carbon fiber microelectrode aimed at the NAcc \[+1.3 anterior, +1.3 lateral (L), −6.5 ventral (V), relative to bregma\] and an Ag/AgCl reference electrode located in the contralateral cortex ([@B19]). A bipolar stimulating electrode (Plastics One) aimed at the ventral tegmental area (−5.2 posterior, +1.1 L, −7 V) was lowered in 100--200 µ[m]{.smallcaps} increments until a 1.0 s, 60 Hz monophasic (4 ms; 700 µA) stimulation train produced a robust DA response in the NAcc. Stimulation evoked DA release was recorded every 5 min for at least 30 min until DA peaks in the NAcc reached stability (three consecutive collections within 10%). Once stability was achieved, rats were injected intraperitoneally with vehicle (0.5% DMSO in 0.9% normal saline) and ensuing changes in DA release were recorded for at least 30 min until DA peak height in the NAcc reached stability. Due to the results of the locomotor studies, we focused on the two higher doses of CNO (2 and 5 mg/kg) for the neurochemical studies, where we also used amphetamine. Rats were then injected intraperitoneally with either a second dose of vehicle (volume equivalent to a 5 mg/kg dose of CNO), 2 mg/kg CNO, or 5 mg/kg CNO, and changes in DA release and uptake (tau) were monitored for 1 h, at which point they were injected with AMPH (1.5 mg/kg). DA release and uptake were determined at 30 min following each treatment and expressed as a percentage of baseline (i.e., the average of the last three collections prior to treatment). The effect of CNO on DA release and uptake for each animal was calculated as (DA~CNO~/DA~Pre-CNO\ Baseline~)/(DA~Vehicle~/DA~Pre-Vehicle\ Baseline~) to control for any effects of the vehicle itself on DA signaling. The effect of AMPH on DA release and uptake in each animal was calculated as (DA~AMPH~/DA~Pre-AMPH\ Baseline~).

Data acquisition {#s3D}
----------------

The electrode potential was linearly scanned (0.4--1.2 V and back to −0.4 V vs Ag/AgCl), and cyclic voltammograms were recorded at the carbon fiber electrode every 100 ms with a scan rate of 400 V/s using a voltammeter/amperometer (Chem-Clamp, Dagan Corporation). The magnitude of stimulated DA release and transporter-mediated uptake kinetics was monitored. DA overflow curves were analyzed, as previously described for peak concentrations of DA and *tau*, using Demon Voltammetry and Analysis software written in LabVIEW language (National Instruments; [@B62]).

HPLC studies {#s3E}
------------

Clozapine (assay 98.9%) was obtained from MP Biomedicals. *N*-desmethylclozapine (assay \>99%) and doxipine HCL internal standard (assay \>99%) were obtained from Tocris Bioscience. For these studies, only CNO 5 mg/kg was tested because it was efficacious in the voltammetry and locomotor studies. In addition, CNO at 1 mg/kg had been previously shown to retroconvert to clozapine in mice ([@B27]). Rats were administered CNO 5 mg/kg, i.p., and 30, 90, 180, or 360 min later (*n* = 4--5/time point) were deeply anaesthetized with sodium pentobarbital (100 mg/kg, i.p.; Fatal Plus, Vortech Pharmaceuticals Ltd.), the heart was exposed, and 8--10 ml of blood was drawn from the right ventricle into a syringe containing EDTA (final concentration, 4 m[m]{.smallcaps}). Blood was transferred to a chilled centrifuge tube and spun at 1000 × *g* at 5°C for 10 min. Plasma was separated into 1 ml aliquots, the HPLC internal standard (doxepin HCL, 20 µl of a 1 µ[m]{.smallcaps} solution) was added, and then aliquots were stored at −80^°^C until further processing. Control plasma, for use in matrix-based calibrators, interference, recovery, and limit of quantification measurements, was collected in the same manner from rats not treated with CNO.

Solid-phase extraction {#s3F}
----------------------

C2 extraction columns (100 mg/ml; ISOLUTE column, Biotage) were conditioned by sequential washing with 0.5 ml of elution solution (10 m[m]{.smallcaps} acetic acid, 5 m[m]{.smallcaps} trimethylamine), 3 × 1 ml methanol and 2 × 1 ml buffer solution rinses (100 m[m]{.smallcaps} sodium phosphate dihydrate, pH 4.6). Plasma (900 µl) was loaded to the columns and allowed to flow under gravity. Columns were then washed sequentially with 2 × 1 ml water and 2 × 0.5 ml acetonitrile, and vacuum dried for 5 min. The analytes were eluted with a 2 × 0.5 ml elution solution, and the combined eluate was evaporated at 30°C under nitrogen. The dry residue was reconstituted in 500 µl of 0.1 [m]{.smallcaps} HCL. The extraction recovery of clozapine, *N*-desmethylclozapine, clozapine N-oxide, and doxepin (internal standard) were between 85% and 95%.

HPLC {#s3G}
----

HPLC analysis was performed by a modification of the method described by [@B39] on a Shimadzu Scientific Instruments Prominence 20A series HPLC and SPDM20A photodiode array. Stock solutions were prepared in 0.1 [m]{.smallcaps} HCl, and calibrators were prepared using blank plasma-matrix. Calibrators were subjected to solid-phase extraction (SPE), as described above for samples. Quantitation was performed by an internal standard methodology, using doxepin as the internal standard. SPE extracts (50 µl) were injected into a 250 × 4.6 mm SupelcoSil, LC-CN (cyano), 5 µm analytical column with a 2 cm guard column, and eluted isocratically with acetonitrile/80 m[m]{.smallcaps} ammonium acetate (pH 7; 75:25 v/v) at a flow rate of 1.2 ml/min. Photodiode array detection was at 254 nm using a 4 nm bandwidth. Matrix and interference studies demonstrated a lack of any coeluting peaks with target analyte peaks. Blank plasma sample chromatograms were subtracted from each sample and calibrator chromatogram to minimize fluctuations in the background chromatogram. The quantitation limits for clozapine, clozapine N-oxide, and *N*-desmethylclozapine were 0.01, 0.03, and 0.03 μ[m]{.smallcaps}, respectively. Quantitative spiking studies using CLZ, *N*-Des, and CNO demonstrated 95--102% recovery of a 0.1 µ[m]{.smallcaps} standard addition. The between-run % coefficient of variation was \<5% for each analyte. Analysis of blank plasma spiked with CNO found a reduction of CNO to clozapine during sample and HPLC processing, which occurs during some processing methods ([@B33]), to be \<2.5%.

Data analysis {#s3H}
-------------

Behavioral and neurochemical data were analyzed in SPSS version 22 (IBM). Details of individual tests are described within the relevant section in Results. Where graphs are displayed, these depict group means ± SEM. Results were considered statistically significant when *p* \< 0.05. On graphs, \* indicates significant difference at the *p* = 0.01--0.05 confidence level, and \*\* indicates *p* ≤ 0.01.

Results {#s4}
=======

Behavioral studies {#s4A}
------------------

### Effects of CNO on startle and PPI {#s4A1}

Results showing the effects of CNO on the ASR and PPI are shown in [Figure 1*A*](#F1){ref-type="fig"}. CNO significantly reduced the ASR to 110 and 120 dB stimuli, but not to stimuli of lower intensities ([Fig. 1*A*](#F1){ref-type="fig"}). CNO had no effect on PPI at any PP level tested ([Fig. 1*B*](#F1){ref-type="fig"}). The effects of CNO on the ASR were analyzed with repeated-measures ANOVA, which showed a significant effect of startle dB (*F*~(3,90)~ = 124.3; p \<0.001), drug treatment (*F*~(1,30)~ = 4.31; *p* = 0.047), and a startle decibel × drug treatment interaction (*F*~(3,90)~ = 3.20; *p* = 0.027). The interaction was investigated with Sidak-adjusted pairwise comparisons, which found that at the 120 and 110 dB level CNO-treated rats had a significantly lower ASR than Veh-treated rats (*p* = 0.037 and *p* = 0.028), but there was no difference at the lower intensities (100 dB, *p* = 0.188; 90 dB, *p* = 0.440). The effects of CNO on PPI were also investigated with a repeated-measures ANOVA, which showed a main effect of PP intensity (*F*~(3,90)~ = 42.04; *p* \< 0.001), no PP × drug treatment interaction (*p* = 0.374), and no main effect of drug (*p* = 0.256). As none of the effects involving CNO (drug treatment) were significant, no further analysis was performed on the PPI data (*n* = 16/group). Together, these results show that CNO at 1 mg/kg significantly reduced the ASR to 120 and 110 dB startling stimuli, but had no significant effect on PPI.

![***A***, ***B***, Startle magnitude and PPI after treatment with CNO. CNO significantly reduced the startle response to 110 and 120 dB startle stimuli (***A***), but had no significant effect on PPI (***B***). \**p* \< 0.05.](enu0051621560001){#F1}

### Effects of CNO on PCP-induced disruptions of ASR and PPI {#s4A2}

Results showing the effects of 2 and 5 mg/kg CNO on PCP-induced disruptions of the ASR and PPI are shown in [Figure 2](#F2){ref-type="fig"}. Pretreatment with CNO had no effect on the PCP-induced increase in the ASR ([Fig. 2*A*](#F2){ref-type="fig"}) or PCP-induced decrease in PPI ([Fig. 2*B*](#F2){ref-type="fig"}). The effects on the ASR were investigated with a two-way repeated-measures ANOVA, which found a main effect of dB (*F*~(3,219)~ = 427.14; *p* \< 0.001) and PCP treatment (*F*~(1,73)~ = 32.517; *p* \< 0.001), and a decibel × PCP treatment interaction (*F*~(3,219)~ = 3.23; *p* = 0.005), but both the CNO treatment × PCP treatment (*F*~(2,73)~ = 1.376; *p* = 0.259) and dB × PCP treatment × CNO treatment (*F*~(6,219)~ = 0.433; *p* = 0.856) interactions were nonsignificant. Sidak test-adjusted pairwise comparisons investigating the effect of PCP treatment found that PCP increased the ASR at all stimuli intensities (90 dB, *p* = 0.001; 100 dB, *p* \< 0.001; 110 dB, *p* \< 0.001; 120 dB, *p* \< 0.001). As no interactions involving CNO were significant, no further analyses were performed. The effects of PCP and CNO on PPI were also investigated with a two-way repeated-measures ANOVA, which showed a main effect of PP intensity (*F*~(3,222)~ = 119.98; *p* \< 0.001) and PCP treatment (*F*~(1,74)~ = 50.90; *p* \< 0.001), and a PP × PCP treatment interaction (*F*~(3,222)~ = 5.89; *p* = 0.001), but that both the CNO treatment × PCP treatment (*F*~(2,74)~ = 0.859; *p* = 0.428) and PP × PCP treatment × CNO treatment (*F*~(6,222)~ = 0.827; *p* = 0.550) interactions were nonsignificant. Sidak-adjusted pairwise comparisons investigating the effect of PCP treatment found that PCP decreased PPI at all PP levels (68 PP, *p* = 0.001; 72 PP, *p* \< 0.001; 76 PP, *p* \< 0.001; 80 PP, *p* \< 0.001). As no interactions involving CNO were significant, no further analyses were performed (*n* = 11--18/group). Combined, these results show that PCP treatment significantly increased the ASR and significantly decreased PPI, and that pretreatment with CNO (at either 2 or 5 mg/kg) had no effect on the changes caused by PCP.

![Startle magnitude and PPI after treatment with CNO and PCP. ***A***, ***B***, PCP significantly increased the startle magnitude (***A***) and disrupted the PPI (***B***). CNO pretreatment had no effect on the disruptive effects of PCP.](enu0051621560002){#F2}

### Effects of CNO on scopolamine-induced disruptions of ASR and PPI {#s4A3}

Results showing the effects of 5 mg/kg CNO on scopolamine-induced disruptions of the ASR and PPI are shown in [Figure 3](#F3){ref-type="fig"}. Pretreatment with CNO had no effect on scopolamine-induced increase in the ASR ([Fig. 3*A*](#F3){ref-type="fig"}) or scopolamine-induced decrease in PPI ([Fig. 3*B*](#F3){ref-type="fig"}). Effects on the ASR were investigated with a two-way repeated-measures ANOVA, which found a main effect of decibel (*F*~(3,84)~ = 248.50; *p* \< 0.001) and scopolamine treatment (*F*~(1,28)~ = 4.874; *p* = 0.036), but that the dB × scopolamine treatment interaction (*F*~(3,84)~ = 0.485; *p* = 0.694) and both the CNO treatment × scopolamine treatment (*F*~(1,28)~ = 0.127; *p* = 0.725) and decibel × scopolamine treatment × CNO treatment (*F*~(3,84)~ = 0.081; *p* = 0.970) interactions were nonsignificant. Sidak-adjusted pairwise comparisons investigating the effect of scopolamine treatment found that scopolamine increased the ASR at all decibel levels (90 dB, *p* = 0.01; 100 dB, *p* = 0.002; 110 dB, *p* \< 0.001; 120 dB, *p* = \<0.001). As no interactions involving CNO were significant, no further analyses were performed. Effects of scopolamine and CNO on PPI were also investigated with a two-way repeated-measures ANOVA, which showed a main effect of PP intensity (*F*~(3,84)~ = 99.86; *p* \< 0.001) and scopolamine treatment (*F*~(1,28)~ = 19.58; p \<0.001), and a PP × scopolamine treatment interaction (*F*~(3,84)~ = 3.851; *p* = 0.012), but that both the CNO treatment × scopolamine treatment (*F*~(1,28)~ = 0.014; *p* = 0.907) and PP × scopolamine treatment × CNO treatment (*F*~(3,84)~ = 0.689; *p* = 0.561) interactions were nonsignificant. Sidak-adjusted pairwise comparisons investigating the effect of scopolamine treatment found that scopolamine decreased PPI at all PP levels (68 PP, *p* = 0.01; 72 PP, *p* = 0.002; 76 PP, *p* \< 0.001; 80 PP, *p* \< 0.001; *n* = 8/group). As no interactions involving CNO were significant, no further analyses were performed. Combined, these results show that scopolamine treatment significantly increased the ASR and significantly decreased PPI, and that pretreatment with CNO had no effect on the changes caused by scopolamine.

![Startle magnitude and PPI after treatment with CNO and scopolamine. ***A***, ***B***, Scopolamine significantly increased the startle magnitude (***A***) and disrupted the PPI (***B***). CNO pretreatment had no effect on the disruptive effects of scopolamine.](enu0051621560003){#F3}

### Effects of CNO on spontaneous locomotion and amphetamine-induced hyperlocomotion {#s4A4}

The effect of CNO on both spontaneous and amphetamine-induced locomotion was determined at the doses of 1, 2, and 5 mg/kg (i.p.). CNO at 1 and 2 mg/kg had no effect on spontaneous locomotion or amphetamine-induced hyperlocomotion ([Fig. 4*A--D*](#F4){ref-type="fig"}). Analyses were performed on the total movement (distance traveled) during the 20 min CNO pretreatment (Veh or CNO) and 120 min post-treatment (Veh or amphetamine) by two-way ANOVA (for all groups, *n* = 8). Sidak-corrected pairwise comparisons found that during the 120 min amphetamine testing period, all amphetamine-treated groups moved significantly more than all non-amphetamine-treated groups (*p* \< 0.001 in all cases). As no main effects of CNO treatment or interactions involving CNO treatment were significant, no further analyses were performed. For all groups, *n* = 8.

![Effects of CNO on spontaneous locomotion and amphetamine-induced hyperlocomotion. Rats were pretreated with either vehicle or CNO, followed 20 min later by either vehicle or amphetamine. ***A--F***, CNO at 1 mg/kg (***A***, ***B***), 2 mg/kg (***C***, ***D***), or 5 mg/kg (***E***, ***F***) had no effect on spontaneous locomotion. Neither 1 nor 2 mg/kg CNO altered amphetamine-induced hyperlocomotion (***B***, ***D***), but 5 mg/kg CNO significantly reduced the effects of amphetamine (***F***). \**p* \< 0.05, \*\**p* \< 0.01.](enu0051621560004){#F4}

The effects of 5 mg/kg CNO on spontaneous locomotion and amphetamine-induced hyperlocomotion are shown in [Figure 4, *E* and *F*](#F4){ref-type="fig"}. Two-way ANOVA finds no significant differences for the total movement during the 20 min CNO pretreatment period \[no effect of CNO treatment (*F*~(1,32)~ = 0.16; *p* = 0.901) and no pre-existing effect in the amphetamine groups or interactions involving amphetamine treatment: amphetamine treatment (*F*~(1,32)~ = 0.476; *p* = 0.496), CNO treatment × amphetamine treatment (*F*~(1,32)~ = 0.205; *p* = 0.654)\]. For the 120 min period after the second treatment, two-way ANOVA finds a main effect of amphetamine treatment (*F*~(1,32)~ = 63.791; *p* \< 0.001), a nearly significant effect of CNO treatment (*F*~(1,32)~ = 4.027; *p* = 0.055), and a significant CNO treatment × amphetamine treatment interaction (*F*~(1,32)~ = 6.489; *p* = 0.017). Sidak-adjusted pairwise comparisons investigating the interaction found no significant difference between the vehicle plus vehicle group and the CNO 5 mg/kg plus vehicle group (*p* = 0.999), and a significant increase in movement in vehicle plus amphetamine group (*p* \< 0.001), and that CNO plus amphetamine group moved significantly more than the saline plus saline group (*p* = 0.001) but significantly less than the saline plus amphetamine group (*p* = 0.019). Together, these results show that CNO at a dose of 5 mg/kg has no effect by itself on spontaneous locomotion, but significantly reduced the hyperlocomotion caused by amphetamine treatment. In order to try and establish the time course of the reduction in amphetamine hyperlocomotion caused by CNO pretreatment, a repeated-measures ANOVA was performed on the locomotor data grouped into 5 min bins ([Fig. 4*A*,*C*,*E*](#F4){ref-type="fig"}). There was a main effect of amphetamine treatment (*F*~(1,28)~ = 63.791; *p* \< 0.001), bin (*F*~(23,644)~ = 3.453; *p* \< 0.001), a bin × treatment interaction (*F*~(23,644)~ = 1.804; *p* = 0.012), and a CNO treatment × amphetamine treatment interaction (*F*~(1,28)~ = 6.489; *p* = 0.017). Sidak-corrected pairwise comparisons performed on each bin found that 6 of the CNO plus amphetamine bins were lower than the saline plus amphetamine bins (bins 8, 13, 16, 20, 22, and 24, *p* \< 0.05 in all cases) and 13 of the CNO plus amphetamine bins are not significantly different from the vehicle plus vehicle bins (5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 21, and 23, *p* \> 0.05 in all cases). The relatively equal distribution of these effects across the 120 min session and lack of a bin × CNO treatment × amphetamine treatment interaction in the repeated-measures ANOVA (*F*~(23,644)~ = 0.671; *p* = 0.876) suggest that the effect of CNO on amphetamine treatment was equal throughout the session rather than, for example, evident only early or late in the session. Together, these results show that CNO at a dose of 5 mg/kg had no significant effect on spontaneous locomotion, but significantly reduced amphetamine-induced hyperlocomotion.

Electrochemical recordings {#s4B}
--------------------------

The effects of CNO on DA release and uptake are shown in [Figure 5](#F5){ref-type="fig"}. CNO alone did not significantly affect electrically stimulated DA release in the NAcc, as determined by one-way ANOVA (Welch's ANOVA for unequal variances, *F*~(2,9.269)~ = 0.221, *p* = 0.805), nor was there an effect on DA uptake (*F*~(2,15)~ = 0.685, *p* = 0.519). By contrast, CNO significantly decreased the effects of AMPH-induced increases in DA release 30 min following administration of AMPH, as determined by one-way ANOVA (*F*~(2,15)~ = 3.935, *p* \< 0.05). *Post hoc* analysis using Bonferroni comparisons found that these effects reached significance only at 5 mg/kg (*p* \< 0.05). Animals treated with 2 mg/kg CNO did not significantly differ from either vehicle-treated (*p* = 0.215) or 5 mg/kg CNO-treated (*p* = 1.000) animals. There was no effect of CNO on DA uptake, as determined by one-way ANOVA (tau; *F*~(2,15)~ = 1.664, *p* = 0.223).

![Effects of CNO on baseline and amphetamine-induced DA signaling. ***A***, ***B***, Examples of 15 s DA overflow curves in vehicle-treated (***A***) and CNO-treated (***B***) rats before (solid) and after (dashed) a dose of 1.5 mg/kg, i.p., [d]{.smallcaps}-AMPH. ***C***, ***D***, CNO did not alter stimulated DA release (***C***) or uptake (***D***) under baseline conditions. ***E***, ***F***, CNO dose-dependently blunted the increased DA release in response to [d]{.smallcaps}-AMPH 30 min after systemic treatment (***E***); however, there were no significant effects on the magnitude of DA uptake inhibition (***F***). \**p* \< 0.05](enu0051621560005){#F5}

HPLC results {#s4C}
------------

CNO levels were maximal (2.148 µ[m]{.smallcaps}) at the 30 min collection time point and steadily diminished to very low levels (0.045 µ[m]{.smallcaps}) at the 360 min collection time point ([Fig. 6*A*](#F6){ref-type="fig"}). This is in line with the relatively rapid clearance of CNO in rodents ([@B6]; [@B27]) compared with humans ([@B29]). Clozapine was detectable at all time points and followed the same pattern as CNO---highest at the 30 min collection time (0.283 µ[m]{.smallcaps}) and then diminishing as a function of time ([Fig. 6*B*](#F6){ref-type="fig"}). Levels of *N*-Des followed a different pattern, remaining at a reasonably steady level (0.059--0.063 µ[m]{.smallcaps}) until diminishing at the 360 min time point ([Fig. 6*C*](#F6){ref-type="fig"}).

![***A--C***, Plasma levels of CNO (***A***), clozapine (***B***), and *N*-Des (***C***) at various time points after the administration of 5 mg/kg CNO.](enu0051621560006){#F6}

Discussion {#s5}
==========

These experiments were conducted to investigate the effects of CNO in male Long--Evans rats. We assessed whether CNO has any effect on acoustic startle ([Fig. 1*A*](#F1){ref-type="fig"}), PPI ([Fig. 1*B*](#F1){ref-type="fig"}), and spontaneous locomotion ([Fig. 4](#F4){ref-type="fig"}). We then assessed whether CNO modifies NMDA (PCP) and muscarinic (scopolamine)-induced disruption of PPI ([Figs. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}), and whether CNO can reduce amphetamine-induced hyperlocomotion ([Fig. 4](#F4){ref-type="fig"}). In order to assess the neurochemical effects, we performed voltammetry in the NAcc to measure the effects of CNO on electrically evoked DA release alone and in response to amphetamine ([Fig. 5*A*,*B*](#F5){ref-type="fig"}). We then processed plasma from CNO-treated rats in order to assess whether CNO is reduced to clozapine or converted into *N*-Des ([Fig. 6*A--C*](#F6){ref-type="fig"}). Our results show that the administration of CNO has multiple effects *in vivo*, and is converted to both clozapine and *N*-Des.

In the startle and PPI experiments, we found that 1 mg/kg CNO reduced the startle response to loud acoustic stimuli ([Fig. 1](#F1){ref-type="fig"}) but had no effect on PPI (a measure of sensorimotor gating; for review, see [@B54]). CNO (2 and 5 mg/kg) had no effect on the disruption to PPI induced by the NMDA antagonist PCP ([Fig. 2](#F2){ref-type="fig"}) or the muscarinic antagonist scopolamine ([Fig. 3](#F3){ref-type="fig"}). Because the higher doses of CNO had no effect on these measures, lower doses were not tested in PPI. In the locomotor studies, CNO alone (at 1 and 2 mg/kg) had no effect on spontaneous or amphetamine-induced locomotion ([Fig. 4](#F4){ref-type="fig"}), but 5 mg/kg CNO pretreatment significantly attenuated amphetamine-induced hyperlocomotion ([Fig. 4*F*](#F1){ref-type="fig"}). Combined, these results show that the administration of CNO within the dose range of 1--5 mg/kg has behavioral effects in Long--Evans rats. The electrochemical experiments mirror these results: although CNO treatment alone did not alter electrically evoked DA release, 5 mg/kg CNO significantly attenuated the increase in evoked DA in response to systemic [d]{.smallcaps}-amphetamine.

In order to establish whether it is possible that our results could be due to the conversion of CNO into clozapine or *N*-Des (as has been reported previously by [@B34]), we processed plasma from rats treated with CNO for the HPLC detection of CNO, clozapine, and *N*-Des. After the administration of 5 mg/kg CNO, plasma CNO levels peaked quickly and fell to very low levels within 360 min ([Fig. 6*A*](#F6){ref-type="fig"}). Clozapine was detectable at all time points ([Fig. 6*B*](#F6){ref-type="fig"}), again with the maximum concentration at 30 min (clozapine concentration was ∼13% of CNO) and fell steadily across the later time points. The level of clozapine at 30 min was approximately one-tenth of the level of CNO at the same time point. A similar ratio has been seen after CNO administration in rats ([@B34]) and humans ([@B30]; [@B11]). Most notably, even though no values were provided, the figure provided by [@B27] shows what appears to be a similar CNO/clozapine ratio and time course in mice at 30 min after the administration of 1 mg/kg CNO ([@B27]). The authors summarized their results by stating that the levels of clozapine produced were nonsignificant. For their experimental manipulation, they are correct in this assumption, as CNO did not produce noticeable effects in a wild-type control group. In our studies, low levels of *N*-Des were also detected at all time points ([Fig. 6*C*](#F6){ref-type="fig"}), but in a seemingly different pattern than the clozapine, staying relatively steady until the 360 min time point. These results are in line with previous reports showing the rapid clearance of CNO in rodents ([@B6]; [@B27]), and the conversion of CNO to clozapine and *N*-Des in rats ([@B34]). Given that in our studies the levels of *N*-Des were always lower than those of either CNO or clozapine, and remained at a stable level until both CNO and clozapine were almost completely absent (360 min), one plausible explanation is that a portion of the CNO is reduced to clozapine, which is then metabolized into *N*-Des ([@B34]; [@B39]).

The detected levels of peripheral plasma clozapine in our rats are comparable to the ranges of clozapine known to have behavioral effects. In rats, 10 mg/kg clozapine (s.c.) leads to a peak unbound plasma level from intracranial microdialysis sampling of ∼0.07 µ[m]{.smallcaps}, and a delayed peak level of 0.008 µ[m]{.smallcaps} *N*-Des ([@B16]). At this dose, clozapine has been shown to reduce amphetamine hyperlocomotion ([@B40]) and reduces the ASR in rats ([@B13]; [@B22]), just as we observed after CNO administration. However, a direct comparison of dose responses to these compounds in the literature is lacking. On the contrary, we did not observe a reversal of the PPI disruptive effects of PCP or scopolamine with CNO administration, as would be expected if clozapine is the main biologically active compound in circulation after CNO administration. However, it would be rash to then conclude that CNO is pharmacologically responsible for the effects we have observed. It has to be considered that when clozapine is administered, CNO is created but not in as great quantities or in the same ratio as we have in the current situation of administering CNO. The presence of CNO may impact the pharmacological action of both clozapine and *N*-Des by simply altering the metabolism, clearance, distribution, and ultimately the time course of action. To attempt to tease this apart with the administration of clozapine or *N*-Des, which themselves will then produce CNO and each other (albeit at different levels), is something that would require a tour de force effort that combines plasma analysis from the same animals that perform the behavior and the time courses of drug metabolism. Therefore, the simplest and most relatable data that should be gathered are a within-study comparison of the effects of CNO in control animals, regardless of the purported known metabolism in any one species. Moreover, both clozapine and *N*-Des have a complex pharmacology. Clozapine is a potent antipsychotic agent, which has submicromolar affinity for \>25 receptors within the CNS, principally serotonergic, muscarinic, dopaminergic, noradrenergic, and histaminergic receptors ([@B14]; [@B49]; [@B41]). *N*-Des also interacts with multiple systems within the CNS but has a notably different pharmacology than clozapine (e.g., muscarinic M1 receptor; [@B52]; [@B17]; [@B55]). The additive or synergistic effects of even undetectable levels of these compounds cannot be assessed or speculated for every circumstance or biological question, especially since the clearance of the compounds will be complicated with the presence of CNO and so needs to be empirically evaluated. In conclusion, despite CNO levels being much higher than the clozapine levels, we cannot make a firm conclusion as to the compound responsible for the behavioral effects after CNO administration.

It is important to emphasize that from the presented results it cannot be unequivocally determined which of the three compounds (CNO, clozapine, or *N*-Des) are responsible for the effects in our study. Further, it would be highly speculative and imprudent for us to suggest that a "safe" or inert dose of CNO can be extrapolated from our experiments. But rather, laboratories using CNO should validate its use in the species, strain, and paradigms being used, and also be aware that an effect of "CNO only" can be unmasked when the system is challenged, as per our amphetamine data ([Fig 4](#F4){ref-type="fig"}). At minimum, our data highlight the need for experiments using CNO to include a CNO-treated control group devoid of DREADD receptors.

Relevance to the DREADD system: is CNO an inert ligand? {#s6}
=======================================================

The results from these studies show that CNO, in male Long--Evans rats, is not an inert ligand. Regardless of whether the behavioral effects we observed are due to CNO itself or to the conversion to clozapine and *N*-Des, the administration of CNO is not without consequence. However, perhaps the biggest concern is indeed the conversion of CNO into clozapine and *N*-Des. We did not perform HPLC analysis on the lower doses of CNO used in the behavioral studies because it is assumed that those doses of CNO would be metabolized in a similar manner and ratio. Moreover, if we were to perform the study with 1 mg/kg CNO but failed to detect clozapine and *N*-Des by our HPLC assay, this could indicate that levels are simply below our detection limits for clozapine and *N*-Des of 0.01 and 0.03 μ[m]{.smallcaps}, respectively. However, this study has been performed in mice, with low but detectable levels of clozapine being detected by liquid chromatography-tandem mass spectrometry after the administration of 1 mg/kg CNO ([@B27]). In combination with a control group that was devoid of DREADD receptors, [@B27] rightly conclude that for their paradigm the level of clozapine was not significant. Combined, the effects of CNO administration on the ASR ([Fig. 1](#F1){ref-type="fig"}), attenuation of the effects of amphetamine ([Figs. 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}) without an effect on spontaneous locomotion in the absence of amphetamine ([Fig. 4](#F4){ref-type="fig"}), and the presence of clozapine and *N*-Des in the plasma ([Fig. 6](#F6){ref-type="fig"}) means that the administration of CNO has no single and clearly predictable effect on one system, but instead is likely to have numerous effects on a diffuse range of systems.

Despite the issues raised, the present findings do not render CNO unusable as an activating ligand in the DREADD system. Rather, it highlights the necessity for incorporation of the appropriate controls and careful consideration of the doses to be administered. An experimental design that includes a group of animals that do not express DREADD receptors, but are given the same dose of CNO as the DREADD-expressing animals, seems a logical and necessary control. However, only a small minority of the current DREADD studies use this control. Instead, most prefer to use a within-subjects design where, in DREADD-expressing animals, the response to a vehicle injection is compared with the response to a CNO injection. In this design, it is impossible to separate out the effects of activation of the DREADD from any unexpected effects of CNO, which could be the enhancement or blockade of the expected result of DREADD activation. In terms of dosing, a wide range of doses (0.2--10 mg/kg) is regularly used in DREADD experiments ([@B2]; [@B23]; [@B45]; [@B1]; [@B4]; [@B21]; [@B37]; [@B56]; [@B7]; [@B8]; [@B18]; [@B31]; [@B47]; [@B63]; [@B10]; [@B25]; [@B38]; [@B42]; [@B50]; [@B61]; [@B26]; [@B35]; [@B36]; [@B44]; [@B51]; [@B57]), and there is seldom any explanation given as to how the dose that was used was decided upon. Using the lowest effectual dose in the assay to be performed, that which in the non-DREADD-expressing animals is experimentally silent, would seem the most straightforward way to minimize any off-target effects of CNO. Finally, perhaps of greatest concern, is the long-term administration of CNO, either in the drinking water or via minipump implantation. Long-term administration of clozapine at doses as low as 1.5 mg/kg/d has been shown to have diverse effects, including reducing 5-HT(2A) receptor mRNA in the striatum, accumbens, and hippocampus ([@B28]).

Our experiments were conducted in adult male Long--Evans rats, which, in addition to being a common outbred strain used in many behavioral experiments, are also the genetic background of the pTH:cre and pChAT:cre rats developed by [@B59]. The generalization of our metabolism results to other rat strains, or to mice, should be done with caution. This is because there are differences in the metabolism of clozapine between species; for example, humans convert considerably more clozapine to *N*-Des than do rats ([@B34]; [@B9]), and the elimination half-life of clozapine is markedly shorter in rats than humans ([@B29]) and also varies according to sex ([@B9]). However, the implications of our results are clear and generalizable: when conducting experiments with CNO, the consideration of possible biological effects of CNO administration must be taken into account. Encouragingly, analogs of CNO that activate DREADDs *in vitro* have been developed ([@B12]), and it is possible that one of these, or a future compound, will not be metabolized into clozapine-related compounds and will have fewer off-target effects than CNO.
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Synthesis {#s7}
=========

The decision was a result of the Reviewing Editor Karen Szumlinski and the peer reviewers coming together and discussing their recommendations until a consensus was reached. A fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision is listed below. The following reviewer(s) agreed to reveal their identity: Susan Ferguson

After consultation with the two experts reviewers of the revised report, I am happy to accept your article for publication in eNeuro, pending a minor revision. I do request prior to full acceptance that the authors make a more concerted effort in the Methods section to explain why the specific CNO dose(s) are employed within each experiment. These explanations can be brief. We all appreciate the authors efforts in revising the manuscript.
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